Idacta-mab INT-001 represents an promising clinical approach for managing selected oncological malignancies. The antigen-binding protein is a distinct process of effect, mainly targeting the CD38 antigen, an membrane https://fannieahqq206099.wikiexpression.com/6406047/idacta_mab_int_001_an_novel_antibody_during_development